echoloc
Get started
echoloc/ Companies/ Vaxcyte

Vaxcyte Tech Stack

Clinical-stage vaccine developer using cell-free protein synthesis for pneumococcal conjugates

Biotechnology Research San Carlos, California 201–500 employees Founded 2013 Public Company
vaxcyte.com LinkedIn

Vaxcyte engineers polyvalent pneumococcal conjugate vaccines (PCVs) using XpressCF®, a cell-free protein synthesis platform licensed from Sutro Biopharma. The company's lead candidate, VAX-31, is a 31-valent PCV in Phase 3 adult and Phase 2 infant trials—designed to cover more disease-causing serotypes than existing vaccines. The tech stack (Veeva QMS/Vault, SAP S/4HANA, HPLC, LC-MS, Azure) and active projects reveal a manufacturing-scale operation wrestling with process robustness, supply-chain security, and GCP compliance—signature challenges of transitioning from clinical to commercial manufacturing.

Tech Stack 26 technologies

Core StackSAP S/4HANA Next.js React GraphQL Playwright Cypress SAP JMP SAP SCM Chromeleon Veeva QMS Veeva Vault Benchling HPLC SDS-PAGE Tecan LC-MS SAP Master Data Management Veeva GC-MS Azure Ironclad CMMS Veeva QualityDocs
ReplacingNetSuite

What Vaxcyte Is Building

◆Challenges

  • Compliance with gdp
  • Troubleshooting assay performance
  • Major erp transformation
  • Secure uninterrupted supply
  • Ensuring compliance of cloud-based gxp systems
  • Meeting aggressive timelines
  • Optimizing synthesis and purification
  • Developing robust conjugation process
  • Improving assay robustness
  • Launch readiness

▲Active Projects

  • Pneumococcal conjugate vaccine process development
  • Support implementation and optimization of spellbook and cocounsel
  • Polysaccharide conjugate vaccine development
  • Global vendor management quality program
  • Vendor qualification and audit program
  • Pcv program
  • Analytical development and stability studies
  • Vaxa1 program
  • Stability program for preclinical and clinical development
  • Clinical trial site identification

Hiring Activity

Accelerating55 roles · 35 in 30d

Department

Engineering
11
Manufacturing
11
Research
11
Ops
4
Finance
3
Product
3
Quality
3
Healthcare
2

Seniority

Senior
22
Director
10
Mid
10
Junior
5
Manager
5
Intern
1
VP
1

Notable leadership hires: Product Launch Lead, Logistics Director

Company intelligence

Find more companies like Vaxcyte by tech stack, pain points and active projects

Get started free

About Vaxcyte

Vaxcyte is a clinical-stage biotechnology company headquartered in San Carlos, California, focused on designing improved vaccines against bacterial pneumococcal disease. Founded in 2013, the company operates across three core vaccine programs: VAX-31 (31-valent PCV for adults and infants), VAX-24 (24-valent PCV for infants), and VAX-XL (earlier-stage, expanded-spectrum candidate). The company owns a proprietary cell-free protein synthesis platform called XpressCF® that enables manufacturing of complex, high-fidelity antigens. With 201–500 employees, Vaxcyte maintains parallel workstreams in clinical development, manufacturing scale-up, analytical validation, and regulatory compliance—hiring across research, engineering, manufacturing, and operations roles.

HeadquartersSan Carlos, California
Company Size201–500 employees
Founded2013
Hiring MarketsUnited States, Switzerland

Frequently Asked Questions

What is Vaxcyte's lead vaccine candidate?

VAX-31, a 31-valent pneumococcal conjugate vaccine in Phase 3 adult trials and Phase 2 infant trials. It covers more serotypes than any PCV currently in clinical development.

What manufacturing platform does Vaxcyte use?

XpressCF®, a cell-free protein synthesis platform exclusively licensed from Sutro Biopharma. It differs from conventional cell-based production and is designed to accelerate vaccine development and improve immunological benefits.

How this profile is built

Vaxcyte's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →

This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.